Recursion Pharmaceuticals
RXRX
157 hedge funds and large institutions have $953M invested in Recursion Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 58 increasing their positions, 43 reducing their positions, and 26 closing their positions.
36% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $765K
35% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 43
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
13% more capital invested
Capital invested by funds: $841M → $953M (+$111M)
0.32% more ownership
Funds ownership: 68.76% → 69.08% (+0.32%)
1% less funds holding
Funds holding: 158 → 157 (-1)
4% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KA
Kinnevik AB
Stockholm,
Sweden
|
+$19.3M |
| 2 |
YRHAM
Yong Rong (HK) Asset Management
Sheung Wan,
Hong Kong
|
+$8.22M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$8.13M |
| 4 |
BlackRock
New York
|
+$6.91M |
| 5 |
LIM
Lingotto Investment Management
London,
United Kingdom
|
+$5.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$11.5M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$9.51M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.72M |
| 4 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$4.39M |
| 5 |
Millennium Management
New York
|
-$4.31M |
RXRX Hedge Fund Activity: Q2 2023 in Review
157 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2023, worth a combined $953M — up 13% from $841M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of RXRX and 25 opened new positions — a net loss of 1 holder — while 43 trimmed existing stakes and 58 added.
The largest buyer was Kinnevik AB, adding an estimated $19.3M. The largest seller was Laurion Capital Management, cutting an estimated $11.5M.
- 157 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2023, down from 158 in Q1 2023.
- Funds reported $953M of Recursion Pharmaceuticals stock for Q2 2023, up 13% quarter-over-quarter.
- 25 funds opened new Recursion Pharmaceuticals positions in Q2 2023 and 26 closed out, a net change of -1 holder.
- The largest Recursion Pharmaceuticals buyer in Q2 2023 was Kinnevik AB, an estimated $19.3M added.
- The largest Recursion Pharmaceuticals seller in Q2 2023 was Laurion Capital Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2023.